Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD96 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD96 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD96 Products |
| Gene Delivery | CD96 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD96 Products |
| Benchmark Ab | Anti-CD96 (Sequence of Clinical Candidates) Recombinant positive control. |
View CD96 Products |
| Validator | CD96 siRNA Set For knockdown verification. |
View CD96 Products |
| Related Target A | TIGIT Synergistic immune checkpoint in the CD155 axis. |
View TIGIT Products |
| Related Target B | CD155 (PVR) Primary ligand for CD96, TIGIT, and CD226. |
View CD155 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand Competition (CD155) | Human/Mouse/Cyno ortholog proteins available with >95% purity for precise SPR/BLI affinity mapping. |
| Receptor Specificity | Homolog panel proteins (TIGIT, CD226) strictly verified by theoretical MW and SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies included for relative affinity comparison. |
| False Positives | Validated siRNA included for specificity checks in cell-based assays. |
Live CD96 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD96 therapeutics is intensifying, with major players shifting focus from traditional single-agent mAbs to combination therapies targeting the broader TIGIT/CD96/CD226 axis. As first-generation therapies reach the clinic, the next wave of R&D is targeting synergistic immune activation in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | GSK, AbbVie (undisclosed candidate) | Solid Tumors, NSCLC | Ligand Blocking Assay (Need high-purity CD96 & CD155) |
| Bispecific Antibody | Various Biotechs | Immunotherapy (PD-1/CD96) | Heterodimer Validation (Need Cross-reactive Abs) |